Phlecs closes funding round for launch of next-generation home-use phototherapy in Europe
Vlissingen, The Netherlands – November 4, 2026 –
Phlecs Light & Health has successfully closed a new funding round to accelerate the development and commercialization of its next-generation home-use phototherapy solution. In the Netherlands, more than 800,000 patients suffer from eczema and psoriasis. Our innovative blue light therapy offers an effective, safe, and convenient treatment option. By expanding into other European markets and the United States, we aim to reach a potential patient population of more than 50 million people.
The funding is a significant milestone for Phlecs and provides the necessary resources to further develop the new home therapy platform, from product development and clinical validation to regulatory procedures, in view of the planned launch in Europe in 2028.
The funding round brings together Impuls Zeeland and a group of private investors from Zeeland within the AddVision network. This combines regional investment expertise with experienced private capital committed to innovation in healthcare.
A shared ambition for sustainable healthcare
Inflammatory skin conditions are chronic conditions that can have a major impact on sleep, daily activities, and quality of life. For many patients, treatment requires continuous or repeated care over many years.
By enabling more treatments at home, Phlecs aims to contribute to a broader transition towards accessible, patient-centered, and sustainable healthcare, while maintaining close collaboration between patients and their care providers.
The successful funding round enables Phlecs and its partners to continue this journey with the ambition to make the next generation of home-use phototherapy available to European patients starting in 2028.
Phototherapy closer to the patient
Phlecs is developing a new generation of home-use phototherapy, designed to make effective light therapy more accessible to patients outside the hospital or dermatology clinic.
The home-use device is being developed in collaboration with a consortium of partners from Zeeland and West Brabant. The development program is supported by an OPZuid grant co-financed by the European Union, the Dutch government, and the Province of Zeeland. It brings together expertise in the fields of medical technology, clinical care, product development, and implementation in healthcare.
The goal is to create a patient-friendly home treatment solution based on Phlecs’ medical blue light technology. This solution offers a UV-free and drug-free approach to inflammatory skin conditions.
Traditional UV phototherapy has played an important role in dermatology for decades and can offer an effective treatment for patients with eczema and psoriasis. However, widespread home use remains a challenge, as the fluorescent lamps traditionally used to generate therapeutic UV light are increasingly suffering from European restrictions on mercury-containing lighting technologies.
Phlecs views this transition as an opportunity to develop a new generation of phototherapy based on modern LED technology, specifically designed for the needs of patients being treated at home.
From clinical innovation to home treatment
Phlecs’ technology utilizes medical blue light instead of ultraviolet radiation. The company has already developed whole-body blue light systems for professional use and is now translating its technology and clinical experience into a dedicated platform for home use.
The new generation builds on Phlecs’ experience in treating inflammatory skin conditions and introduces technologies aimed at improving treatment control, ease of use, and personalization in the home environment.
David Aubert, CEO of Phlecs Light & Health, said:
“Completing this funding round is a significant step for Phlecs. It enables us to transition from a proven clinical technology to a new generation of phototherapy that can ultimately be used by patients at home. Together with our investors, our regional partners, and the OPZuid consortium, we now have the foundation to bring this innovation through the development and clinical validation phases to the European market.” The funding will support the next development phases, including the engineering and industrialization of the device for home use, clinical studies, regulatory certification, and preparations for the market launch.
Michel Carol, Project Manager at AddVision and leader of the Zeeland Informal Investing Network, added:
“The Zeeland Informal Investing Network (ZIIN) bridges the gap between Zeeland investors and innovative Zeeland companies. Entrepreneurs play a crucial role in the financing and further development of young and innovative companies.
Phlecs’ ambition and plans align with ZIIN’s vision; it is a young and innovative company with great potential for Zeeland. The development of the new platform for home therapy involves close collaboration with a large number of partners from Zeeland and West Brabant. Therefore, the investors are happy to support Phlecs in this development and its commercial rollout.”
Rosco Ephraim, Investment Manager at Inpuls Zeeland, added:
“Phlecs demonstrates how technological innovation and societal impact come together. Through Impuls Zeeland, we supported Phlecs at an early stage with financing and their grant application, and subsequently gave them a warm introduction to the Zeeland network. This has led to a great collaboration and a joint investment with Zeeland investors. Our role therefore goes beyond financing alone: we connect entrepreneurs with the right knowledge, partners, and investors to advance both innovations and the Zeeland economy.”
About Phlecs Light & Health
Phlecs Light & Health is a Zeeland-based medical technology company that develops innovative light-based treatments for inflammatory skin conditions. Building on technology from Philips Research, Phlecs develops medical blue light solutions designed to offer a UV-free and drug-free treatment option for conditions such as atopic dermatitis, psoriasis, and chronic itching.
The company collaborates with healthcare providers, research institutions, and technology partners to develop phototherapy from clinical treatment to personalized treatment at home.
About AddVision:
AddVision stands for creating regional impact by making a significant contribution to the various transition issues in Zeeland.
Together with KplusV, AddVision is the driving force behind the informal investors network in Zeeland.
Informal investors are entrepreneurs who make risk-bearing investments in young and innovative companies. The investors contribute not only money but also their knowledge, experience, and network, thereby playing an important role in the development of these enterprises. The investor network aligns with the existing ecosystem in Zeeland and works closely with, among others, Impuls Zeeland, Dockwize, and Rabobank. Zeeuws Informal Investing Netwerk | AddVision Projectmanagement
About Impuls Zeeland:
About the development program
The Phlecs home phototherapy program is being developed in collaboration with a consortium of partners from Zeeland and West Brabant. The project is supported by the OPZuid program and co-financed by the European Union, in support of innovation and economic development in the Southern Netherlands.
(https://www.phlecs.com/home-phototherapy/ )
Contact
Phlecs Light & Health
Vlissingen, Nederland
www.phlecs.com
David.aubert@phlecs.com.
This post is also available in:
